Shona
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Products Categories
Featured Products
Mapiritsi eLenopril Anopa Simba Kudzora Kudzvinyirira Kweropa uye Hutano hweMwoyo

Mapiritsi eLenopril Anopa Simba Kudzora Kudzvinyirira Kweropa uye Hutano hweMwoyo
Telmisartan Zviri nani antihypertensive Kudzivirira renal

Telmisartan Zviri nani antihypertensive Kudzivirira renal
Flumazenil A Selective GABAA Receptor Antagonist uye ayo Therapeutic Applications

Flumazenil A Selective GABAA Receptor Antagonist uye ayo Therapeutic Applications
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Dabrafenib A Targeted Therapy yeBRAF-Mutated Cancers

Dabrafenib A Targeted Therapy yeBRAF-Mutated Cancers
Tirzepatide Dual GLP-1 uye GIP Receptor Agonist yeWeight Management uye Glycemic Control

Tirzepatide Dual GLP-1 uye GIP Receptor Agonist yeWeight Management uye Glycemic Control
Cisapride Gastric Stimulant yeIndigestion uye Digestive Disorders

Cisapride Gastric Stimulant yeIndigestion uye Digestive Disorders
YK-11 Iine Simba SARM yeMuscle Building, Simba Gains, uye Myostatin Inhibition

YK-11 Iine Simba SARM yeMuscle Building, Simba Gains, uye Myostatin Inhibition
Ostarine (MK-2866) Yakasiyana-siyana SARM yeKukura Kwemhasuru, Kurasikirwa Kwemafuta, uye Kudzoreredzwa Kwemuviri

Ostarine (MK-2866) Yakasiyana-siyana SARM yeKukura Kwemhasuru, Kurasikirwa Kwemafuta, uye Kudzoreredzwa Kwemuviri
MK-677 Unique Compound yeKukura Kwetsandanyama, Kutsungirira, uye Kudzoreredza

MK-677 Unique Compound yeKukura Kwetsandanyama, Kutsungirira, uye Kudzoreredza
0102030405
Dabrafenib A Targeted Therapy yeBRAF-Mutated Cancers
Dabrafenib A Targeted Therapy yeBRAF-Mutated Cancers
Dabrafenib A Targeted Therapy yeBRAF-Mutated Cancers
Dabrafenib A Targeted Therapy yeBRAF-Mutated Cancers

Dabrafenib A Targeted Therapy yeBRAF-Mutated Cancers

Mutengo: USD 50-60 / kg

  • Product Name Dabrafenib
  • CAS Nha. 1195765-45-7
  • MF C23H20F3N5O2S2
  • MW 519.561
  • EINECS 1592732-453-0
  • Density 1.443
  • Boiling point 653.726 °C pa760 mmHg
Taura nesu
product details

Tsanangudzo Yakadzama

Dabrafenib is an orally bioavailable inhibitor yeprotein yeB-raf (BRAF) uye inoshandiswa semushonga unorwisa kenza. Iyo inosarudza inonangana negomarara rakabatana neshanduro yakashandurwa yeBRAF gene. Ichi chinyorwa chinoongorora maitiro echiito, zviratidzo zvekiriniki, uye mashandisirwo edabrafenib mukurapa magomarara akasiyana.

I. Kunzwisisa Dabrafenib:
A. Inhibitor yeB-raf (BRAF) protein
B. Mechanism of action: Kuvhara chiratidzo cheprotein chisina kujairika uye kudzora kukura kwesero

17159473034104h3

II. Clinical zviratidzo:

A. Monotherapy:

Isingaverengeki kana metastatic melanoma ine BRAF V600E shanduko

B. Combination therapy ne trametinib:

BRAF V600E-yakanaka isingagadzirike kana metastatic melanoma

Metastatic isiri-diki yesero kenza yemapapu

Metastatic anaplastic thyroid cancer

Zvisingarambiki kana metastatic solid tumors


III. Mechanism of Action:

A. Kusarudza kusunga uye kuvharirwa kweB-raf

B. Kudzivirirwa kwebundu cell proliferation ine mutated BRAF gene


IV. Kurapwa kwegomarara rethyroid:

A. Rumwe rudzi rwegomarara rethyroid rapararira kumatishu ari pedyo kana dzimwe nhengo dzemuviri

B. Kare kurapwa(s) kuramba


V. Kinase Inhibitor Kirasi:

A. Dabrafenib senhengo ye kinase inhibitors

B. Kuvharisa mapuroteni asina kujairika kudzivirira kenza kuwanda kwemasero


Dabrafenib mushonga wakanangwa unoshandiswa mukurapa kweBRAF-mutated cancers. Seinhibitor yeprotein yeB-raf (BRAF), inonangana nemabundu maseru ane mutated BRAF gene, ichitadzisa kuwanda kwavo. Dabrafenib inoratidzwa kune isingagadziriswi kana metastatic melanoma, isiri-diki yekenza yemapapu yemapapu, kenza yeaplastic yethyroid, uye isingagadziriswi kana metastatic yakasimba tumors. Combination therapy ne trametinib inowedzera kuwedzera mashandisirwo ayo. Nekunzwisisa kuchinjika kwemajini mumasero egomarara, marapirwo anonangwa senge dabrafenib anoita basa rakakosha mukuvandudza mhedzisiro yekurapa uye kumisa kupararira kwekenza maseru.

Tsanangudzo

1715947563669qd1